APUS
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -2.26 | $0 | -$2M |
| 2025 Q4 | -0.09 | $0 | -$4M |
| 2025 Q3 | -1.40 | $0 | -$2M |
| 2025 Q2 | -2.60 | $0 | -$3M |
| 2025 Q1 | -0.35 | $0 | -$20,313 |
| 2024 Q4 | -0.27 | $0 | -$99,616 |
| 2024 Q3 | -0.29 | $0 | -$186,755 |
| 2024 Q2 | -0.39 | $0 | -$184,055 |